Painchek Ltd (ASX: PCK) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Painchek Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $54.96 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.41 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return 26.47%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Painchek Ltd (ASX: PCK)
    Latest News

    Scientist looking at a laptop thinking about the share price performance.
    Healthcare Shares

    Why did this ASX biotech stock explode 36% today?

    This ASX nano-cap healthcare share has leapt 47% in just a week.

    Read more »

    Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
    Share Gainers

    What the heck is going on with the PainChek (ASX:PCK) share price?

    It's been a strange few days on the ASX for PainChek...

    Read more »

    A boy looks up and points his fingers to the sky in celebration pose.
    Healthcare Shares

    The PainChek (ASX:PCK) share price is rising on its latest announcement

    Shares in PainChek Ltd are gaining today after the company has received regulatory clearances for its app, PainChek Infant.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the Painchek (ASX:PCK) share price is charging 13% higher

    The PainChek Ltd (ASX: PCK) share price is soaring today after the app developer received TGA approval for its latest…

    Read more »

    high share price
    Share Gainers

    Why Lake Resources, PainChek, Z Energy, & Zip shares are rising today

    Lake Resources N.L (ASX:LKE) and Zip Co Ltd (ASX:Z1P) are two of four ASX shares climbing higher on Wednesday. Here's…

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the Painchek (ASX:PCK) share price is edging higher today

    The PainChek (ASX: PCK) share price rose today against the market as the company announced its half-year report. We take…

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Share Market News

    Why the Painchek (ASX:PCK) share price lifted today

    The Painchek (ASX: PCK) share price was up more than 4% at close of trade after the company released its…

    Read more »

    Share Fallers

    PainChek (ASX:PCK) share price lower despite Ramsay (ASX:RHC) partnership

    The PainChek Ltd (ASX:PCK) share price is dropping lower on Friday despite announcing a partnership with Ramsay Health Care Limited…

    Read more »

    PCK ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Painchek Ltd

    Painchek Ltd is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate pain with carers. It operates in one segment namely sale of pain assessment solutions.

    PCK Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Nov 2023 $0.04 $0.00 0.00% 839,777 $0.04 $0.04 $0.04
    27 Nov 2023 $0.04 $-0.01 -23.26% 3,018,367 $0.04 $0.04 $0.04
    24 Nov 2023 $0.04 $0.00 0.00% 319,479 $0.04 $0.04 $0.04
    23 Nov 2023 $0.04 $0.00 0.00% 1,631,399 $0.04 $0.04 $0.04
    22 Nov 2023 $0.04 $0.00 0.00% 1,082,723 $0.05 $0.05 $0.04
    21 Nov 2023 $0.04 $0.00 0.00% 1,223,701 $0.05 $0.05 $0.04
    20 Nov 2023 $0.05 $0.00 0.00% 2,111,609 $0.05 $0.05 $0.05
    17 Nov 2023 $0.05 $0.00 0.00% 445,249 $0.05 $0.05 $0.04
    16 Nov 2023 $0.04 $0.00 0.00% 1,446,398 $0.04 $0.04 $0.04
    15 Nov 2023 $0.04 $0.00 0.00% 509,915 $0.04 $0.04 $0.04
    14 Nov 2023 $0.04 $0.00 0.00% 713,110 $0.04 $0.04 $0.04
    13 Nov 2023 $0.04 $0.00 0.00% 1,590,536 $0.04 $0.04 $0.04
    10 Nov 2023 $0.04 $0.00 0.00% 967,473 $0.04 $0.04 $0.04
    09 Nov 2023 $0.04 $0.00 0.00% 3,228,051 $0.04 $0.04 $0.04
    08 Nov 2023 $0.04 $0.00 0.00% 3,323,545 $0.04 $0.04 $0.04
    07 Nov 2023 $0.04 $0.00 0.00% 484,046 $0.04 $0.04 $0.04
    06 Nov 2023 $0.04 $0.00 0.00% 1,594,081 $0.04 $0.04 $0.04
    03 Nov 2023 $0.04 $0.00 0.00% 397,091 $0.04 $0.04 $0.04
    02 Nov 2023 $0.04 $0.00 0.00% 2,049,057 $0.04 $0.04 $0.04
    01 Nov 2023 $0.04 $0.00 0.00% 576,412 $0.04 $0.05 $0.04
    31 Oct 2023 $0.05 $0.00 0.00% 3,360,690 $0.05 $0.05 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Nov 2023 Adam Davey Issued 477,327 $20,000
    Director remuneration. Est. value, 477,327 Rights
    09 Nov 2023 Philip Daffas Issued 5,966,587 $250,000
    Director remuneration. Est. value, 19,404,907 Performance Rights
    09 Nov 2023 John Murray Issued 954,654 $40,000
    Director remuneration. Est. value, 954,654 Performance Rights
    09 Nov 2023 Ross Harricks Issued 477,327 $20,000
    Director remuneration. Est. value, 477,327 Performance Rights
    09 Nov 2023 Cynthia Payne Issued 477,327 $20,000
    Director remuneration. Est. value, 477,327 Performance Rights
    27 Sep 2023 Cynthia Payne Buy 675,676 $20,000
    Conversion of securities. Est. value
    27 Sep 2023 Cynthia Payne Exercise 675,676 $20,000
    Conversion of securities. Est. value
    27 Sep 2023 Ross Harricks Buy 675,676 $20,000
    Conversion of securities. Est. value
    27 Sep 2023 Ross Harricks Exercise 675,676 $20,000
    Conversion of securities. Est. value
    27 Sep 2023 John Murray Buy 1,351,351 $40,000
    Conversion of securities. Est. value, As per announcement on 04-10-2023
    27 Sep 2023 John Murray Exercise 1,351,351 $40,000
    Conversion of securities. Est. value
    27 Sep 2023 Adam Davey Buy 675,676 $20,000
    Conversion of securities. Est. value, As per announcement on 04-10-2023
    27 Sep 2023 Adam Davey Exercise 675,676 $20,000
    Conversion of securities. Est. value
    13 Feb 2023 Philip Daffas Issued 8,445,945 $228,040
    Issue of securities. Est., 13,438,320 Rights
    13 Feb 2023 John Murray Issued 1,351,351 $36,486
    Issue of securities. estd., 1,351,351 Rights
    13 Feb 2023 Cynthia Payne Issued 675,676 $18,243
    Issue of securities. Est. value, 675,676 Performance Rights
    13 Feb 2023 Adam Davey Issued 675,676 $18,243
    Issue of securities. 675,676 Performance Rights, ESTD.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Adam Stuart Davey Non-Executive Director Sep 2014
    Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, ASX listings, asset sales and purchases, transaction due diligence and director duties. This has been achieved through holding various roles within different organisations, including chairman, managing director, non-executive director, major shareholder and corporate adviser to the board. Mr Davey is a non-executive director of Ensurance Limited and the Agency Group Australia Ltd.
    Mr Philip Daffas Chief Executive OfficerManaging Director Sep 2016
    Mr Daffas is a global business leader and people manager with an international career spanning more than 25 years with leading blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector on a global basis. Philip's earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio-Rad Laboratories and CEO of Applied Physiology, an Australian software start up company in the intensive care monitoring sector.
    Mr John Murray Non-Executive ChairmanNon-Executive Director Sep 2016
    Mr Murray has 25 years experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original and leading venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has considerable experience as an investor and a non-executive director of high growth, technologybased companies. He possesses a broad understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also brings 12 years experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of a number of successful technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.
    Mr Ross Harricks Non-Executive Director Sep 2016
    Mr Harricks has experience in the commercialisation of medical products which spans over forty years and over three continents. His experience includes the marketing and commercialising of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. In 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers. In Australia Mr Harricks has been a director of ResMed Limited and cofounder of AtCor Medical where he completed an Australian initial public offering in 2005 leading the company until 2007. He was a director of VentraCor from 2005 to 2009. Mr Harricks works with Australian medical and technology companies assisting in commercialisation of their products into the US and EU markets. His unique expertise and experience includes strategic advising on the best path to early international market endorsement and adoption, and on providing hands-on help with implementation in the American and European markets.
    Ms Cynthia Payne Non-Executive Director Mar 2022
    Ms Payne brings 30 years executive leadership experience as well as board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a large private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices. Ms Payne is currently a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia. She is a Certified Chair with The Board Advisory centre.
    Ms Lisa Dadswell Company Secretary Dec 2022
    Iain McAdam Chief Financial Officer
    Lisa Dadswell Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    PETERS INVESTMENTS PTY LTD 118,650,000 9.14%
    Hsbc Custody Nominees (Australia) Limited 67,710,244 5.22%
    J&E CONSULTING PTY LTD 38,003,125 2.93%
    DR KRESHNIK HOTI 37,717,411 2.91%
    MR MUSTAFA ABDUL WAHED ATEE 37,003,125 2.85%
    Bnp Paribas Noms Pty Ltd <Drp> 29,143,853 2.25%
    MR PHILIP DAFFAS 21,524,560 1.66%
    MR CRAIG ROBERT WILLIAMSON 19,255,683 1.48%
    G & G CHILCOTT PTY LTD <G & G CHILCOTT S/F A/C> 13,927,169 1.07%
    NANJOP PTY LTD <THE MURRING FAMILY A/C> 12,914,735 0.99%
    MR ROBERT ANTHONY HEALY i 12,857,143 0.99%
    Citicorp Nominees Pty Limited 11,675,234 0.90%
    MR ROBERT ANTHONY HEALY 11,000,000 0.85%
    MR SHANNON JOHN GORMAN 10,463,516 0.81%